Korea's biohealth exports set a record in 2024, but the number that should hold a medical buyer's attention is not the headline total. It is where that demand is now going, and how quickly the map is being redrawn.
The topline first, because it frames everything else. Korea's biohealth exports reached US$27.9 billion in 2024, a record, up 10.3% from US$25.3 billion the year before. Medical devices accounted for roughly US$6 billion of that figure, a category worth reading on its own terms rather than folding into the broader biohealth story, since the devices trade answers to different regulatory logic and a different buyer than pharmaceuticals do.
Two forces sit behind the device number. One is a recovery in in-vitro diagnostics; the other is steady growth across general devices. The diagnostics point is worth pausing on, because it is easy to misread. Testing volumes swung violently through the pandemic years, and a return to record territory could look like more of the same volatility. It is the opposite. With pandemic distortion gone, in-vitro diagnostics now rests on genuine underlying demand. For a buyer, that translates into volumes and pricing that can actually be planned against, a steadier base than the category has offered in years.
The United States remains the single largest destination for Korea's exports. Around it, two figures describe the same market from different angles, and they are easy to set against each other by mistake. Advanced markets (the United States and Europe taken together) account for 39.5% of exports. Separately, the share going to markets outside the top five has climbed to 43.3%. These are not competing claims. The first measures a bloc of mature Western economies; the second measures everything beyond the five largest destinations. Both can be large at once, and read together they describe a trade that is still anchored in the West while spreading steadily into newer markets across Southeast Asia, the Middle East and beyond.
That diversification is the part a compliance-minded buyer should weigh most carefully. A supplier base selling into that widening set of destinations is, by necessity, one that has learned to satisfy several regulatory regimes rather than one. The upside is a manufacturer accustomed to documentation and certification demands; the caution is that certification held for one market does not automatically carry to another, and the burden of confirming that sits with the buyer.
Korea's device makers are, for the most part, mid-sized firms already geared to regulated export markets rather than the household names of the pharmaceutical side. Their fit for a given buyer turns on details (product quality, the state of a compliance dossier, real manufacturing capacity) that resist assessment from a distance. This is where Korea's official medical and health exhibitions earn their place. They concentrate qualified suppliers in one setting, and let an international buyer shortlist candidates and examine their certification paperwork first-hand before committing to a relationship.
Tell us your sourcing category and we'll prepare a matched supplier shortlist, with no obligation.
Request an invitation →
Data Intelligence Lab